InvestorsHub Logo
Followers 55
Posts 10607
Boards Moderated 6
Alias Born 11/14/2019

Re: None

Thursday, 09/29/2022 2:55:48 PM

Thursday, September 29, 2022 2:55:48 PM

Post# of 36
GARDEN CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced an update to the expectations for U.S. Food and Drug Administration (FDA) approval of LungFit® PH for the treatment of persistent pulmonary hypertension of the newborn, or PPHN. https://www.beyondair.net/news-and-events/press-releases/detail/153/beyond-air-provides-regulatory-update-for-lungfit-ph
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent XAIR News